# Medanta Chairman's Pharma Panel Role Sparks Conflict Debate

> Medanta's Naresh Trehan faces conflict of interest claims after joining government pharma marketing panel.
- Title: Medanta Chairman's Pharma Panel Role Sparks Conflict Debate
- Summary: Medanta's Naresh Trehan faces conflict of interest claims after joining government pharma marketing panel. Advocacy group demands replacement of Medanta…
- Keywords: medanta, naresh trehan, pharma marketing panel, conflict of interest, government committee, nppa, ucpmp, news, india, Chairman's, Pharma, Panel
- Source: mint — https://livemint.com/companies/people/medanta-chairman-naresh-trehan-s-appointment-to-pharma-marketing-panel-sparks-conflict-of-interest-debate-11793017334181.html
- Author: Trisha Bhattacharya
- Published: 2026-10-26T13:34:35+00:00
- Read time: 1 min
- Topics: medanta, naresh trehan, pharma marketing panel, conflict of interest, government committee, nppa, ucpmp, news, india
## Medanta Chairman's Panel Appointment
Advocacy group questions Medanta chairman Naresh Trehan's inclusion in government pharma marketing panel.

> Medanta MD Naresh Trehan’s inclusion in pharma marketing panel is now being questioned by advocacy group over conflict-of-interest concerns
## Committee Composition
The panel includes former Union health secretary Preeti Sudan, NITI Aayog member M Srinivas, and Medanta chairman Naresh Trehan.
## Committee's Mandate
The committee must examine current monitoring systems and recommend changes to improve transparency and compliance within two months.
## Advocacy Group's Concerns
Group cites 2018 NPPA reports on overcharging at Medanta hospitals as reason for potential conflict of interest.

> NPPA
## Conflict of Interest Claims
Group argues Trehan's financial interests could affect committee's impartiality in pharma regulation decisions.
## Government Response
Department has not yet replaced Trehan despite group's objections to committee's independence.
## Panel's Impact
Committee's recommendations could shape pharma marketing oversight in India's healthcare system.
## Current Status
Group has asked government to reconstitute panel to ensure independence from potential conflicts.
## Regulatory Context
India's pharma marketing rules were updated in 2024 to strengthen implementation framework after 2015 voluntary code.

> UCPMP 2024
## Key takeaway

Advocacy group demands replacement of Medanta chairman Naresh Trehan from pharma marketing panel due to potential conflicts of interest.